Dr. Toni K. Choueiri is the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer Institute/Brigham and Women’s Hospital and an Associate Professor of Medicine at Harvard Medical School. He is the Co-Leader of the Kidney Cancer Program at Dana-Farber/Harvard Cancer Center and President of the Medical Staff at Dana-Farber. He serves on the National Comprehensive Cancer Network (NCCN) Kidney Cancer Panel, the GU Steering Committee (GUSC) Task Force of the National Cancer Institute (NCI), and is Chairman of the Medical and Scientific Steering Committee of the Kidney Cancer Association.Dr. Choueiri is interested in developing novel therapies and biomarkers in GU malignancies. His research also focuses on epidemiology, diagnosis and treatment outcomes of prostate and urinary cancers using large scale approaches such as meta-analyses from available published trials or national databases. His work has been funded by the American Society of Clinical Oncology, the Harvard Kidney Cancer SPORE, the NCI, and Industry partners. He has over 400 PubMed-listed publications and is the overall principal investigator of multiple national and international phase I-III trials in GU cancers.
Novel therapies in genitourinary cancers with a focus on kidney cancers
Dr. Choueiri is interested in the clinical and molecular predictors of outcome to therapies in renal cancers.
Dana-Farber Cancer Institute450 Brookline AvenueBoston MA, 02215Get Directions